Halozyme Beats Q3 Earnings But Stock Falls 16% on Guide
Halozyme Therapeutics posted record Q3 2026 revenue of $493 million, up 39% year-over-year, and beat adjusted EPS estimates, but the stock fell 16% in response. Investors had priced in a larger guidan
Halozyme Beats Q3 But Stock Falls 16% on Small Raise
NEW YORK, November 7 —
Halozyme Therapeutics, Inc. (HALO) delivered record revenue of $493 million and beat adjusted EPS estimates, then suffered a 16% single-session selloff, leaving shares at $103.63, below every price at which CEO Helen Torley had sold stock in the prior three weeks. The question for investors is whether that gap is a rational repricing or an overreaction at a royalty engine now trading at under 10x forward earnings.
- Q3 2026 total revenue: $493M, up 39.2% year-over-year; royalties $341M, up 44.5% [8-K]
- Adjusted EPS $2.39, beat consensus by $0.10; full-year EPS guide raised to $8.75, $9.05 midpoint
- Post-earnings stock at $103.63; CEO sold 120,000 shares in Sept, Oct at $107.01, $113.69
A Royalty Engine Running Hot, Then Punished
Halozyme licenses its ENHANZE technology, a recombinant enzyme that transiently dissolves the skin's hyaluronic acid matrix, allowing large-molecule biologics to be injected subcutaneously rather than infused intravenously, to partners including Johnson & Johnson, argenx, and Roche. Those three drove the 44.5% royalty surge in Q3, with J&J's subcutaneous Darzalex, argenx's Vyvgart Hytrulo, and Roche's Phesgo leading volume. This is a capital-light toll-road model: Halozyme builds no drugs, runs no trials, collects fees when partners sell. Three consecutive EPS beats, $1.60, $2.28, and now $2.39, suggest the toll keeps rising. The selloff, then, was not about what happened in Q3; it was about what management implied for Q4 and beyond.
The Guidance Raise That Wasn't Enough
The full-year revenue ceiling moved to billion from billion, a $15 million lift on a business already running at a $493 million quarterly rate. The EPS guide went to $8.75, $9.05 from $8.65, $9.00. At the new EPS midpoint, HALO trades at roughly 13x 2026 earnings, or at $103.63 spot, closer to 9.7x on a forward basis. For a royalty platform that grew revenue 39% year-over-year, neither multiple looks stretched. But a stock up 82.7% year-to-date going into the print was priced for a larger guide step-up, and when that didn't arrive, Leerink downgraded. The gap between operational performance and investor expectation is the actual story, and the guidance math is where it crystallized.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| HALO | $11.8B | 9.8x | +51.9% |
| NBIX | $16.7B | 13.6x | +8.0% |
| ALNY | $20.9B | 14.0x | -64.8% |
| PTCT | $5.5B | 20.5x | -8.5% |
| AGIO | $1.8B | n/a | -30.5% |
| CYTK | $7.5B | n/a | -10.8% |
What the CEO's Sales Calendar Implies for the Next Checkpoint
Torley exercised options at $18.41 and sold 60,000 shares on October 6-8 at open-market prices of $107.90, $113.69, per SEC filings. She had sold another 60,000 shares in September at $107.01, $108.67. Combined with smaller sales by director Matthew L. Posard, net insider activity totaled $22.10 million in sales against zero purchases over the 90-day window. Every one of those transactions cleared at prices above where HALO trades today. Option exercises routinely generate planned sales, so the pattern is not automatically bearish, but the volume, timing, and the fact that the post-earnings price now sits below each of those exit points will keep short interest, already at 15.8% of float, elevated heading into Q4. The number to watch: whether royalties sustain above $341 million next quarter, confirming the growth rate rather than marking Q3 as the peak. Run the free Halozyme Therapeutics, Inc. deep-dive →
Current fundamentals, valuation and filing history for Halozyme Therapeutics, Inc. (HALO) are tracked on its Basis Report page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Halozyme Q3 2026 earnings results
Halozyme Therapeutics reported record Q3 2026 revenue of $493 million, up 39.2% year-over-year, with royalties reaching $341 million, up 44.5%. The company delivered adjusted EPS of $2.39, beating consensus estimates by $0.10, and raised its full-year EPS guidance to $8.75, $9.05.
Why did Halozyme stock fall after beating earnings?
Despite beating earnings, the stock fell 16% because investors expected a larger guidance raise. The company raised full-year revenue guidance by only $15 million to $1.925 billion, disappointing for a stock already up 82.7% year-to-date. The gap between operational performance and investor expectations crystallized in the guidance numbers.
What technology does Halozyme license?
Halozyme licenses a technology called ENHANZE, which allows large pharmaceutical molecules to be injected under the skin instead of into the vein. The company doesn't develop or test drugs itself; instead, it collects fees when partners like Johnson & Johnson, argenx, and Roche sell products using the technology.
What is Halozyme's stock valuation?
At the post-earnings price of $103.63, Halozyme trades at roughly 9.7x forward earnings or 13x 2026 earnings. For a royalty platform that grew revenue 39% year-over-year, neither multiple appears stretched based on operational fundamentals.
What do insider stock sales suggest about Halozyme?
CEO Helen Torley sold 120,000 shares between September and October at prices ranging from $107.01 to $113.69, all above the post-earnings price of $103.63. Combined with other insider sales, net insider activity totaled $22.10 million in sales against zero purchases over the 90-day window, with short interest already at 15.8% of float.
Halozyme Therapeutics posted record Q3 2026 revenue of $492.97 million, beat adjusted EPS estimates by $0.10, and raised full-year guidance — then watched its stock fall 16% on the session as Leerink issued a downgrade and investors found the guidance raise smaller than expected, leaving shares below every price at which the CEO had sold over the prior three weeks.